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Epstein-Barr virus (EBV) infects >90% of the human population within the ﬁrst 2 decades of life and establishes
reversible latent infection in B cells. The stimuli that lead to switching from latent to lytic EBV infection in vivo
are still elusive. Group A streptococci (GAS) are a common cause of bacterial pharyngotonsillitis in children and
adolescents and colonize the tonsils and pharynx of up to 20% of healthy children. Thus, concomitant presence of
EBV and GAS in the same individual is frequent. Here, we show that EBV carriers who are colonized with GAS
shed EBV particles in higher numbers in their saliva, compared with EBV carriers not colonized with GAS. Mes-
senger RNA levels of the master lytic regulatory EBV gene BZLF1 were more frequently detected in tonsils from
EBV carriers colonized with GAS than from EBV carriers not colonized. Heat-killed GAS, potentially mimicking
GAS colonization, elicited lytic EBV in latently infected lymphoblastoid cell lines (LCLs) partially via Toll-like re-
ceptor 2 triggering, as did puriﬁed GAS peptidoglycan. Thus, colonization by GAS might beneﬁt EBV by increas-
ing the EBV load in saliva and thereby enhancing the likelihood of EBV spread to other hosts.
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More than 90% of the adult population is persistently
and asymptomatically infected with Epstein-Barr virus
(EBV), a human B-lymphotropic γ-herpesvirus [1].
Primary infection with EBV is acquired mainly in
childhood via saliva [1]. The oropharynx is the portal
of entry and exit, where the palatine tonsils act as reser-
voir for EBV [2–4]. In its latent form in B cells, EBV ex-
presses a limited number of genes, does not replicate,
and its DNA is propagated to daughter cells during cell
division. By contrast, in its lytic form, EBV expresses
genes required for replication and generation of infec-
tious virus particles resulting in host cell lysis and virus
release [5]. The default state of EBV infection is the
latent form, which is reversible, permitting the creation
of new viral particles and transmission to other hosts
[6]. The mechanisms responsible for switching to the
lytic form in vivo are not completely understood.
EBV is associated with Burkitt lymphoma (BL),
Hodgkin disease (HD), and posttransplantation lym-
phoproliferative disease [7]. These B-cell tumors display
distinct patterns of EBV latency gene expression [8].
The oncologic potential of latent EBV is indicated by
its unique capacity to growth transform B cells in vitro
to lymphoblastoid cell lines (LCLs) [1]. Thus, disruption
of latency is not only essential to enable transmission of
EBV to other hosts but might be an important factor to
limit EBV-induced B-cell lymphoproliferation.
Being immunocompromised increases the risk of
EBV-associated B-cell tumors [9]. But nonimmunocom-
promised individuals may also develop EBV-associated
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BL or HD. EBV-associated HD is more likely to develop when
primary EBV infection occurs in adolescence and manifests as
infectious mononucleosis with an exuberant immune activation
[10]. In endemic BL, >95% of the tumors are EBV positive, and
they are epidemiologically linked to Plasmodium falciparum
malaria, resulting in chronic immune activation [11]. The
pattern-recognition receptor Toll-like receptor 9 (TLR9) is abun-
dantly expressed in B cells, and it senses DNA and the malaria
parasite’s pigment hemozoin [12–14].We recently demonstrated
that TLR9 activation of B cells inhibits lytic EBV during primary
infection and inhibits the switching of latent to lytic EBV in
chronic infection in vitro [15, 16].
Group A streptococci (GAS) colonize tonsils and the
pharynx of up to 20% of healthy children [17]. Considering the
high prevalence of EBV and GAS, concomitant presence of
both microorganisms in the same individual is frequent. TLR9
senses bacterial DNA and is crucial for controlling GAS infec-
tions [18]. One may thus reason that the presence of GAS in
tonsils may direct the EBV life cycle toward latency, thereby
impairing EBV transmission to other hosts via saliva.
Here, we investigated the inﬂuence of GAS on EBV’s life
cycle and salivary shedding and the mechanisms involved.
METHODS
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The Ethics Commission of the
Canton of Zurich approved the study (StV 40/05). All subjects
or their caregivers provided written informed consent.
Cell Culture
The EBV-producer cell line B95.8, Akata BL cells, tonsillar
mononuclear cells (TMCs), and LCLs were maintained in
Roswell Park Memorial Institute 1640 medium (Sigma-Aldrich,
Buchs, Switzerland) with 10% heat-inactivated fetal bovine
serum (Life Technologies, Zug, Switzerland), 1% L-glutamine,
and 1% penicillin-streptomycin, referred to hereafter as R10.
Enzyme-Linked Immunosorbent Assay (ELISA)
Interleukin 6 (IL-6) or interleukin 10 (IL-10) levels were mea-
sured using human IL-6 or IL-10 ELISA kits (R&D Systems,
Abingdon, United Kingdom) following the manufacturer’s
instructions.
DNA Extraction and EBV DNA Detection
Saliva samples were obtained and DNAwas extracted as reported
elsewhere [19]. EBV DNA levels were determined by quantitative
real-time PCR (qPCR) targeting the conserved EBV BamHI W
region, as reported elsewhere [20].
RNA Extraction and qPCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen)
following the manufacturer’s instructions. After DNase I
treatment, 1 µg of total RNA was used as template for reverse
transcription by use of a High-Capacity cDNA Reverse Tran-
scription Kit (Life Technologies). qPCR for human and EBV
gene messenger RNA (mRNA) was performed using speciﬁc
primers and probes for IL-6, IL-10, or BZLF1, as reported else-
where [15], and for TLR1–10 (Life Technologies). All reactions
were performed on a real-time PCR machine (7900HT;
Life Technologies) with TaqMan Gene Expression Master Mix
(Life Technologies). The relative gene expression was calculated
for each gene of interest by using a ΔΔCT method, where CT
values were normalized to the value for the housekeeping gene
hydroxymethylbilane synthase (HMBS) [15].
Isolation of TMCs and EBV Serology
TMCs were isolated from palatine tonsils obtained from pa-
tients who underwent routine tonsillectomy, as reported else-
where [21]. The EBV serologic characteristics of the TMC
donors were determined using the Immunodot-Mono G and
Mono M kit according to the manufacturer’s instructions
(Ruwag Diagnostics, Bettlach, Switzerland).
Preparation of Stock EBV
Supernatant of B95.8 cells was obtained as reported elsewhere
[21] and stored at −80°C. The cell-free supernatants con-
tained approximately 1 × 108/mL EBV DNA as evaluated by
qPCR [20].
GAS Strains
The well-characterized clinical isolate M1T1 GAS strain 5448
[22] was grown to logarithmic phase in Todd-Hewitt broth
(Becton Dickinson, Allschwil, Switzerland) containing 2% yeast
extract (THY; Oxoid, Pratteln, Switzerland) and was resuspend-
ed in Roswell Park Memorial Institute 1640 medium at a ﬁnal
concentration of 2 × 109 colony-forming units/mL. Bacteria
were killed by heating (at 85°C for 60 minutes) or by sonication
(Sonoplus HD2070; Bandelin Electronic, Berlin, Germany) with
20 kHz at 70 W (amplitude, 100%) for 15 minutes on ice.
Detection of GAS Colonization
Explanted tonsils were rolled over 5% sheep blood agar that
was incubated for 48 hours. GAS was identiﬁed by latex aggluti-
nation for Lanceﬁeld group A (Bio-Rad, Cressier, Switzerland)
and detection of pyrrolidonyl peptidase production, using L-
pyrrolidonyl-beta-naphthylamid (0.7%) disks (Oxoid, Pratteln,
Switzerland).
Stimulation of EBV-Infected Cells With GAS
To model acute infection, TMCs plus B95.8 culture superna-
tants were used, and to model persistent infection, LCLs and
Akata cells [23] were used. LCLs were established from TMCs
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by infection with B95.8 EBV. Heat-killed or sonicated GAS at a
multiplicity of infection (MOI) of 100 or 20 µg/mL of GAS
peptidoglycan (Toxin Technology, Sarasota, FL) was added
for 24 hours. Apoptosis was assessed using a PE Annexin V
Apoptosis Detection Kit I according to the manufacturer’s in-
structions (Becton Dickinson). To neutralize TLR2, LCLs were
preincubated with anti-TLR2 polyclonal antibodies (LabForce
AG-InvivoGen, Nunningen, Switzerland).
Flow Cytometry
For TLR2 detection, ﬂuorescein isothiocyanate (FITC)–labeled
anti-TLR2 monoclonal antibodies (TL2.1; LabForce AG-Inviv-
oGen) were used, and FITC-labeled mouse immunoglobulin
G2a (Becton Dickinson) was used as isotype control. For TLR2
and BZLF1 detection, following TLR2 staining, cells were ﬁxed
with 2% paraformaldehyde (Sigma-Aldrich) and permeabilized
using 0.4% Triton X-100 before adding anti-BZLF1 antibodies
(BZ1; Santa Cruz Biotechnology, Heidelberg, Germany)
followed by PE-labeled rabbit anti-mouse immunoglobulin G1
(Santa Cruz Biotechnology). Data on apoptosis or TLR2 and/or
BZLF1 detection were collected using a FACSCanto II (Becton
Dickinson) and were analyzed using FlowJo software.
Statistical Analyses
Analyses of statistical signiﬁcance were based on a 2-tailed
paired or unpaired Student t test, Wilcoxon signed rank test,
Mann–Whitney U test, or χ2 test. Differences with a P value of
<.05 were regarded as statistically signiﬁcant.
RESULTS
Saliva From EBV-Infected GAS-Colonized Individuals
Contained More EBV Than Saliva From EBV-Infected
Individuals Not Colonized With GAS
We asked whether salivary EBV shedding is inﬂuenced by colo-
nization with GAS. Thus, we assayed saliva from EBV-infected
individuals who were or were not colonized with GAS by using
qPCR targeting EBV DNA to detect viral DNA contained in
intact EBV particles. We detected EBV in 7 of 12 GAS-colo-
nized individuals (58%; median age, 6.0 years [range, 2.2–15.0
years]; mean age, 6.2 years) and 9 of 15 GAS-negative individu-
als (60%; median age, 5.3 years [range, 3.1–13.8 years]; mean
age, 6.0 years). The number of EBV DNA copies in saliva from
GAS-colonized EBV-infected individuals was higher than that
in saliva from noncolonized individuals (P = .03; Figure 1).
More-Frequent BZLF1 mRNA Expression in Tonsils From GAS-
Colonized Than From Noncolonized EBV-Infected Individuals
The EBV load in saliva may reﬂect distinct EBV replication in
oropharyngeal epithelial cells, mucosa-associated B cells, or
both. Since determination of EBV replication in primary epi-
thelial cells is not feasible, we measured BZLF1 mRNA expres-
sion in tonsils. BZLF1 is an immediate-early lytic EBV gene,
the expression of which is sufﬁcient to initiate EBV replication.
Tonsil tissues from 5 of 8 GAS-colonized individuals expressed
BZLF1 mRNA (62.5%; median age, 5.3 years [range, 2.8–6.8
years]; mean age, 4.9 years), in contrast to 1 of 8 GAS-negative
individuals (12.5%; median age, 4.8 years [range, 3.1–6.0
years]; mean age, 4.8 years; P = .04; Figure 2A). IL-6 and IL-10
mRNA expression levels determined by human speciﬁc qPCRs
showed no signiﬁcant differences between GAS-positive and
GAS-negative tonsils (Figure 2B and 2C), suggesting a similar
inﬂammation status.
Heat-Killed but Not Sonicated GAS Induced Lytic EBV In Vitro
After EBV Exposure
Heat-killed GAS are intact bacteria that mimic colonizing GAS.
In contrast, sonication disrupts GAS, resulting in fragmentation
and release of bacterial cell wall components and DNA, mim-
icking an acute GAS infection during which GAS are lysed by
both the immune system and antibiotics. We inoculated TMCs
with EBV B95.8 and concomitantly stimulated them with heat-
killed or sonicated GAS at a MOI of 100. We then measured
EBV and HMBS mRNA expression levels by qPCR 24 hours
after inoculation with EBV. Levels of BZLF1 mRNA in TMCs
24 hours after stimulation with heat-killed GAS were higher
than in nonstimulated TMCs or in TMCs stimulated with soni-
cated GAS (P = .03; Figure 3A). Furthermore, heat-killed GAS
did not affect latent EBV (LMP1 and EBNA3C; data not
Figure 1. Saliva from Epstein-Barr virus (EBV)–infected group A strepto-
coccus (GAS)–colonized individuals contained more EBV particles than
saliva from EBV-infected noncolonized individuals. The number of EBV
DNA copies per milliliter in saliva samples from EBV carriers who under-
went routine tonsillectomy was determined by quantitative real-time poly-
merase chain reaction after DNase I treatment. Results for GAS-positive
(n = 12) and GAS-negative (n = 15) individuals were compared. P values
were calculated using the Mann–Whitney U test. *P = .03.
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shown), IL-6, and IL-10 mRNA expression in TMCs, compared
with no stimulus (Figure 3B and 3C). In contrast, sonicated
GAS increased IL-6 and IL-10 mRNA expressions in TMCs,
compared with no stimulus or heat-killed GAS (P = .03;
Figure 3B and 3C). Thus, neither heat-killed nor sonicated GAS
inﬂuenced latent EBV gene expression. In contrast, heat-killed
GAS strongly induced lytic EBV infection in TMCs exposed de
novo to EBV, whereas sonicated GAS did not. The latter
induced strong cytokine gene expression in TMCs, whereas
heat-killed GAS did not.
Heat-Killed GAS Induced Lytic EBV and Caused Cell Death
in Latently EBV-Infected B Cells
Next, we asked whether GAS modulates EBV persistent B-cellular
infection. We used LCLs as a model for persistent (latent) EBV
infection and stimulated them with heat-killed or sonicated GAS
at a MOI of 100. EBV and mRNA expression levels of human
genes were measured by qPCR 24 hours later. BZLF1 mRNA
levels in LCLs exposed to heat-killed GAS were higher (P = .02)
than in LCLs with or without exposure to sonicated GAS
(Figure 4A).
Figure 2. BZLF1 messenger RNA (mRNA) in tonsils from Epstein-Barr virus (EBV)–infected group A streptococcus (GAS)–colonized individuals was more
frequently detectable than in noncolonized individuals. Levels of BZLF1 (A ), IL-6 (B ), and IL-10 (C ) mRNA expression in tonsil tissues from EBV-seropositive
patients who underwent routine tonsillectomy were analyzed by quantitative real-time polymerase chain reaction. Results for GAS-positive (n = 8)
and GAS-negative (n = 8) individuals were compared. BZLF1 expression values above the lower detection limit were considered positive, and those below
the lower detection limit were considered negative. P values were calculated using the χ2 test. *P = .04.
Figure 3. Heat-killed but not sonicated group A streptococcus (GAS) induced lytic Epstein-Barr virus (EBV) after de novo in vitro EBV exposure. Tonsillar
mononuclear cells (TMCs) were inoculated with supernatants from B95.8 cells (EBV-producer cells). Concomitantly, heat-killed or sonicated GAS were
added, and then cell pellets were harvested and subjected to quantitative real-time polymerase chain reaction to determine expression of BZLF1 (A), IL-6
(B ), and IL-10 (C ) messenger RNA (mRNA) expression. Results shown were pooled from TMCs from 6 donors and are expressed as mean values ± standard
error of the mean. P values were calculated using a Wilcoxon signed rank test. *P = .03.
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We asked whether the increased BZLF1 mRNA levels after
exposure to heat-killed GAS were associated with B-cell death.
We assessed late apoptosis by determining the percentage of
7-aminoactinomycin D (7-AAD)–stained cells by ﬂow cytome-
try in LCLs following stimulation or no stimulation. Exposure
to heat-killed GAS for 24 hours resulted in higher percentages
of 7-AAD–stained cells as compared to exposure to sonicated
GAS or controls (P = .008; Figure 4B). There were no differenc-
es in percentages of early apoptotic cells as assessed by ﬂow
cytometry after staining with Annexin V and 7-AAD. This was
conﬁrmed by assessing cell viability, using the Trypan blue
exclusion method (not shown). The number of EBV DNA
copies after DNase I treatment in the supernatants of LCLs
exposed to heat-killed GAS were higher than in controls
(P = .02; Figure 4C), corroborating our above-described in vivo
observations of higher EBV copies in tonsils of GAS-colonized
individuals. Exposure to sonicated GAS resulted in lower EBV
DNA copies, compared with no exposure (P = .02; Figure 4C).
This is in line with our previous study showing that TLR9
triggering results in suppression of switching from latent to
lytic EBV. Sonicated GAS contain increased levels of GAS
DNA, which has been recently demonstrated to trigger TLR9
and subsequently induce proinﬂammatory cytokine expression
[18, 24].
Heat-killed GAS did not affect the levels of EBNA3C latent
EBV (not shown) or IL-6 (Figure 4D), although it slightly upre-
gulated IL-10 mRNA expression (Figure 4E). Similarly, after de
novo EBV exposure, sonicated GAS increased IL-6 (P = .02;
Figure 4D) and IL-10 mRNA expression in LCLs, compared
with no stimulus (P = .03; Figure 4E), as well as IL-6 and IL-10
protein levels (Figure 4F and 4G).
We wondered whether heat-killed or sonicated GAS exhibit-
ed similar effects on EBV-carrying BL cells as on LCLs. We
chose Akata cells because they represent a well-established
model for studying the switching from latent to lytic EBV in
vitro. We analyzed BZLF1 mRNA expression 24 hours after
treatment with heat-killed or sonicated GAS by qPCR. In con-
trast to LCLs, levels of BZLF1 mRNA in Akata cells exposed to
heat-killed GAS were not altered, whereas exposure to sonicat-
ed GAS signiﬁcantly decreased endogenous levels of BZLF1
mRNA expression (Figure 4H). These results suggested that
sonicated GAS might trigger TLR9. Sonicated GAS samples
contain genomic DNA with unmethylated CpG motifs known
to trigger TLR9 [18, 24], and triggering of TLR9 results in sup-
pression of lytic induction in Akata cells [15, 16]. No difference
in the percentage of 7-AAD stained cells was observed in the
cells exposed to heat-killed or sonicated GAS (Figure 4I).
Primary B Cells and LCLs Expressed TLR2, in Contrast to
Akata Cells
Gram-positive bacteria, such as GAS, are recognized by TLR2
on the cell surface and by TLR9 in endosomes [18, 24]. TLRs
are key players in innate immunity and are involved in the rec-
ognition of pathogens and microbial products leading to activa-
tion of antimicrobial effector pathways [25]. TLR2 generally
forms heterodimers with TLR1 or TLR6, which recognize pep-
tidoglycan and lipoteichoic acids from gram-positive bacteria
[26]. We asked whether the differences in lytic EBV gene ex-
pression were due to distinct expression proﬁles of TLRs. Thus,
we analyzed TLR expression in primary B cells, LCLs, and
Akata cells (Figure 5A). Primary B cells, LCLs, and Akata cells
expressed TLR1, TLR6, TLR7, TLR9, and TLR10 mRNA,
whereas TLR5 mRNA expression was detected at extremely low
levels in primary B cells and was not detected in LCLs and
Akata cells. TLR2, TLR3, and TLR4 mRNA was detected at ex-
tremely low levels in Akata cells, in contrast to primary B cells
and LCLs. Similar to TLR2mRNA, TLR2 protein was expressed
in LCLs but not in Akata cells (Figure 5B), and the mean ﬂuo-
rescence intensity on LCLs was higher than on Akata cells
(Figure 5C), as determined by ﬂow cytometry. Since heat-killed
Gram-positive bacteria are known TLR2 ligands [27] above
results suggested that heat-killed GAS might induce lytic EBV
infection in LCLs via TLR2 activation.
Heat-Killed GAS and GAS Peptidoglycan Induce Lytic
EBV via TLR2
Exposure of LCLs to either heat-killed GAS, puriﬁed GAS pep-
tidoglycan used as control for the GAS cell wall component
peptidoglycan, or sonicated GAS did not change the percentag-
es of TLR2-positive cells as determined by ﬂow cytometry
(Figure 6A and 6B upper panel left). Percentages of BZLF1-pos-
itive cells in LCLs exposed to heat-killed GAS were higher than
in nonexposed LCLs or in LCLs exposed to sonicated GAS
(Figure 6A and 6B), corroborating mRNA expression ﬁndings
(Figure 4A), and exposure to GAS peptidoglycan showed
results similar to those for the heat-killed GAS. The propor-
tions of BZLF1-positive cells showed around a 4-fold higher
increase among TLR2-positive cells, compared with TLR2-neg-
ative cells, after exposure to heat-killed GAS or GAS peptido-
glycan (Figure 6B). We conﬁrmed that exposure of LCLs to
GAS peptidoglycan resulted in similar upregulation of BZLF1
and IL-10 mRNA as heat-killed GAS, compared with no expo-
sure (Figure 6C). Similar results were obtained using 2 other
TLR2 ligands, staphylococcal lipoteichoic acid and staphylo-
coccal peptidoglycan (Supplementary Figure 1) [28, 29].
Finally, anti-TLR2 polyclonal neutralizing antibodies inhibited
upregulation of BZLF1 and IL-10mRNA expression (Figure 6C)
in LCLs exposed to heat-killed GAS or GAS peptidoglycan.
DISCUSSION
We examined the inﬂuence of GAS oropharyngeal colonization
on EBV’s life cycle. We found that (1) EBV carriers shed more
EBV particles in their saliva when colonized with GAS, (2)
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Figure 4. Heat-killed group A streptococcus (GAS) induced lytic Epstein-Barr virus (EBV) and caused increased cell death of latently EBV-infected B
cells. Levels of BZLF1 (A), IL-6 (D), and IL-10 (E) messenger RNA (mRNA) expression in lymphoblastoid cell lines (LCLs) were analyzed by quantitative real-
time polymerase chain reaction (qPCR) 24 hours after exposure. B, 7-aminoactinomycin D (7-AAD)–stained LCLs were analyzed by ﬂow cytometry 24 hours
after exposure. The numbers of EBV DNA copies in culture supernatants from LCLs were analyzed by qPCR 24 hours after exposure (C ). Interleukin 6 (IL-6;
F ) and interleukin 10 (IL-10; G ) concentrations in supernatants from LCLs were measured by enzyme-linked immunosorbent assay (ELISA). The results
shown were pooled from LCLs from 7 donors, from 4 donors (done in duplicate), and from 6 donors for qPCR, ﬂow cytometry, and ELISA, respectively, and
are expressed as mean values ± standard error of the mean (SEM). P values were calculated by the Wilcoxon signed rank test. *P < .05, **P < .01. H,
Levels of BZLF1 mRNA expression in Akata Burkitt lymphoma (BL) cells were analyzed by qPCR 24 hours after exposure to heat-killed or sonicated GAS. I,
7-AAD–stained Akata BL cells were analyzed by ﬂow cytometry 24 hours after exposure. Results shown were from Akata BL cells pooled from 3 experi-
ments and are expressed as mean values ± SEM. The P value was calculated using a paired Student t test. *P < .05.
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EBV’s immediate-early lytic gene BZLF1 mRNA expression
was more frequent in tonsils from GAS-positive EBV carriers
than from GAS-negative EBV carriers, (3) heat-killed GAS
induced lytic EBV in tonsils during primary infection with
EBV in vitro and in persistently EBV-infected LCLs resulting
in cell death, and (4) heat-killed GAS and puriﬁed GAS pepti-
doglycan induced lytic EBV in LCLs via TLR2 activation. Thus,
GAS colonization of the oropharynx might beneﬁt EBV by in-
creasing the salivary EBV load and thereby enhancing the like-
lihood of EBV spread to other hosts.
Our observation that concomitant GAS colonization resulted
in higher salivary EBV shedding is unprecedented. Salivary
EBV shedding lasts at least 6 months after primary EBV infec-
tion manifesting as infectious mononucleosis [10, 30, 31].
Frequent and abundant salivary EBV shedding is observed in
EBV-infected children with tonsillar hypertrophy [19], a
condition that is associated with more-frequent GAS coloniza-
tion [32]. Lytic EBV replication in the oropharynx may occur
in epithelial cells, which act as ampliﬁers [33] after acquiring
EBV from tonsillar or other local mucosa-associated B cells
[34]. Investigation of lytic EBV replication in oropharyngeal ep-
ithelial cells has not been successful. Thus, we assessed the
effect of GAS carriage in tonsils from EBV carriers. We found
that GAS carriage was associated with signiﬁcantly higher im-
mediate-early lytic gene BZLF1 mRNA expression, which
induces switching from latent to lytic EBV [1, 6, 35]. In vitro,
upregulation of BZLF1 is induced by sodium butyrate [36], 12-
O-tetradecanoylphorbol-13-acetate [37], cross-linking of B-cell
receptor [38, 39], or the antiinﬂammatory cytokine transform-
ing growth factor β [40]. Based on IL-6 and IL-10 expression,
the inﬂammation status of tonsils from GAS-colonized individ-
uals did not differ from that of tonsils from noncolonized
Figure 5. Primary B cells and lymphoblastoid cell lines (LCLs) expressed Toll-like receptor 2 (TLR2), in contrast to Akata BL cells. A, Messenger RNA
(mRNA) expression levels of TLR1–TLR10 in peripheral blood and tonsillar primary B cells, LCLs (n = 4), or Akata BL cells were analyzed by quantitative
real-time polymerase chain reaction. Representative data of ﬂow cytometry for TLR2 on LCLs and Akata BL cells (B) and the mean ﬂuorescence intensity
(MFI) from Akata BL cells pooled from 3 experiments and LCLs from 3 donors (C) are shown. The closed histogram, dotted line, and solid line represent un-
stained cells, isotype control, and anti-TLR2 antibody, respectively. The P value was calculated using an unpaired Student t test. *P < .05.
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individuals in this study. Thus, enhanced EBV lytic replication
was not due to a lower proinﬂammatory or higher antiinﬂam-
matory state of the tonsils.
Intriguingly, we found that heat-killed GAS and sonicated
GAS exhibited contrasting effects on both EBV and immune
activation. Whereas heat-inactivated GAS induced lytic EBV,
Figure 6. Heat-killed group A streptococcus (GAS) and GAS peptidoglycan induced lytic Epstein-Barr virus via Toll-like receptor 2 (TLR2). A, Representa-
tive ﬂow cytometry ﬁndings for TLR2 and BZLF1 in lymphoblastoid cell lines (LCLs) unstimulated or simulated with heat-killed GAS, GAS peptidoglycan, or
sonicated GAS. B, Percentages of TLR2-positive cells, BZLF1-positive cells, and BZLF1-positive cells among TLR2-positive cells and TLR2-negative cells fol-
lowing no treatment or treatment with heat-killed GAS or GAS peptidoglycan. C, Levels of BZLF1 and IL-10 RNA expression in LCLs following no exposure
or exposure to heat-killed GAS, GAS peptidoglycan, or sonicated GAS without or with antecedent anti-TLR2 polyclonal neutralizing antibodies (anti-TLR2
pAb) treatment were analyzed by quantitative real-time polymerase chain reaction. Results shown are from LCLs from 6 donors and are expressed as mean
values ± standard error of the mean. P values were calculated using a Wilcoxon signed rank test. *P < .05.
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sonicated GAS did not. Sonicated GAS, by contrast, increased
the expression of IL-6 in TMCs, whereas heat-inactivated GAS
did not. Thus, heat-inactivated GAS—intact GAS bacterial cells
that may therefore mimic GAS colonization—seem to activate
the innate immunity differently from sonicated GAS and have
an opposite inﬂuence on EBV. GAS DNA found in sonicated
GAS suspensions triggers TLR9 and subsequently induces
proinﬂammatory cytokine expression [18, 24]. Activation of
Akata cells was diminished when a TLR9 antagonist was added
(Supplementary Figure 2). This is compatible with our observa-
tion of increased IL-6 expression in TMCs exposed to sonicated
GAS but not in TMCs exposed to heat-killed GAS. Important-
ly, we recently demonstrated that TLR9 triggering suppresses
switching from latent to lytic EBV [15, 16].
The upregulation of BZLF1 following exposure to heat-killed
GAS was only approximately 1.5-fold but was highly reproduc-
ible, implying that only a small fraction of B cells was provoked
to switch to lytic EBV infection. Indeed, we found that around
1% of LCL cells upregulated BZLF1 expression after exposure
to heat-killed GAS. An alternative reason for the increase in the
level of EBV shedding in GAS-colonized children might be that
they have an immunological difference that allows coincident
GAS persistence and higher EBV secretion. Nevertheless, no
such difference was observed for IL-6, IL-10 (Figure 2B and
2C), and TNF-α mRNA expression levels (Supplementary
Figure 3A). Surprisingly, heat-killed GAS did not induce
switching to lytic EBV in Akata cells, which are commonly
used as a model to study the switching from latent to lytic EBV.
Thus, we hypothesized that Akata cells may differ from
primary B cells and LCLs in their expression of TLRs. Indeed,
we found that Akata cells expressed TLR2 at remarkably lower
levels, if at all, than primary B cells and LCLs. Exposure of
LCLs to GAS peptidoglycan, a known ligand for TLR2, pro-
voked similar expression of BZLF1 as heat-killed GAS. Upregu-
lation of BZLF1 was around 4-fold higher in TLR2-positive B
cells, compared with TLR2-negative B cells. Importantly, anti-
TLR2 neutralizing antibodies completely abrogated upregula-
tion of BZLF1 following exposure to heat-killed GAS or GAS
peptidoglycan. This strongly suggested that heat-killed GAS
and GAS peptidoglycan upregulated BZLF1 expression in LCLs
via TLR2 triggering. Finally, we showed that other known
TLR2 ligands, namely staphylococcal lipoteichoic acid and pep-
tidoglycan [28, 29], also induced BZLF1 mRNA expression in
LCLs, suggesting the engagement of TLR2 results in lytic reacti-
vation of EBV.
Our novel ﬁndings imply that TLR2 triggering may disrupt
EBV’s default state of latency. This seems to be beneﬁcial for
EBV since it allows EBV to spread to other hosts. However, it
may put EBV latency and the survival of the host cell at stake.
In view that TLR2-expressing EBV-infected cells are likely to
undergo switching to lytic EBV, selection of EBV-infected B-
cells subsets with lower or no expression of TLR2 may take
place over time. Notably, we found that TLR2 mRNA levels in
EBV-negative BL cells were at least 5-fold higher than in EBV-
positive BL cells (Supplementary Figure 3B), suggesting that cells
expressing low TLR2 levels may have been more likely to survive
than cells expressing higher levels of TLR2. Alternatively, EBV
may induce downregulation of TLR2 expression, thereby
preventing switching to lytic infection and securing its latent
state. Indeed, the expression of TLR2 in tonsillar B cells de-
creased in a time-dependent fashion after inoculation with EBV
(Supplementary Figure 3C). Thus, TLR2 signal transduction
may contribute to balancing latent and lytic EBV infection.
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